content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">As filed with the Securities and Exchange Commission on January
  24, 2025</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: right">Registration No. 333-_______</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 7pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 14pt Times New Roman; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
  SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 18pt Times New Roman; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 24pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Aquestive Therapeutics, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: bottom; width: 34%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="vertical-align: top; width: 33%">
      <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>30 Technology Drive</B></P>
      <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Warren, NJ 07059</B></P></TD>
      <TD STYLE="vertical-align: bottom; width: 33%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>82-3827296</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of <BR>
  Incorporation or Organization)</FONT></TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(Address of Principal Executive <BR>
  Offices)</P>
      <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(Zip Code)</P></TD>
      <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(</B>I.R.S. Employer Identification No.)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as
  amended</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>A. Ernest Toth, Jr.</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Chief Financial Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Aquestive Therapeutics, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>30 Technology Drive</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Warren, NJ 07059</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>(908) 941-1900</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(Telephone number, including area code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><I>Copies of all communications to<B>:</B></I></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Lori J. Braender</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Chief Legal Officer and Corporate Secretary</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Aquestive Therapeutics, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>30 Technology Drive</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Warren, NJ 07059</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>908-941-1900</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark whether the
  registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 46%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Large accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD>
      <TD STYLE="width: 54%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Non-accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&yacute;</FONT></FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Smaller reporting company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&yacute;</FONT></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Emerging growth company <FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Wingdings">o</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Registration Statement is being filed
  by Aquestive Therapeutics, Inc. (the &ldquo;Registrant&rdquo;) for the purpose of registering an additional 3,656,549 shares of common
  stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of the Registrant available for issuance under the Aquestive Therapeutics,
  Inc. 2018 Equity Incentive Plan, as amended (the &ldquo;2018 Plan&rdquo;), pursuant to provisions of the 2018 Plan providing for an automatic
  increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan. The Registrant previously filed
  with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) registration statements on Form S-8 on July 27, 2018 (File
  No. 333-226399), January 8, 2021 (File No. 333-251984), January 7, 2022 (File No. 333-262051), January 18, 2023 (File No. 333-269292),
  August 9, 2023 (File No. 333-273857), and February 12, 2024 (File No. 333-277015) (collectively, the &ldquo;Prior Registration Statements&rdquo;)
  registering shares of Common Stock issuable under the 2018 Plan. This Registration Statement relates to securities of the same class as
  those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding
  Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements
  are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by
  this Registration Statement below.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman; margin: 0pt 0; text-align: justify">Item 3. Incorporation of Documents by Reference.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents, as originally filed
  with the Commission by the Registrant, are incorporated herein by reference; provided, however, that any reports or portions thereof that
  are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall
  not be deemed incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(a)</FONT></TD><TD STYLE="text-align: justify">The Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with
  the Commission on March 5, 2024;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(b)</FONT></TD><TD STYLE="text-align: justify">The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with
  the Commission on May 7, 2024;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(c)</FONT></TD><TD STYLE="text-align: justify">The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the
  Commission on August 6, 2024;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(d)</FONT></TD><TD STYLE="text-align: justify">The Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with
  the Commission on November 4, 2024;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(e)</FONT></TD><TD STYLE="text-align: justify">The
  Registrant&rsquo;s Current Reports on Form 8-K, filed with the Commission on March 15, 2024, March 21, 2024, April 1, 2024, April 22,
  2024, April 29, 2024, June 6, 2024, June 21, 2024, July 25, 2024, August 14, 2024, September 27, 2024, October 16, 2024, October 24,
  2024, October 25, 2024, November 7, 2024, December 2, 2024, and December 19, 2024; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman">(f)</FONT></TD><TD STYLE="text-align: justify">The description of the Common Stock contained in the Registrant&rsquo;s Registration Statement on Form
  8-A (File No. 001-38599) filed with the Commission on July 20, 2018, pursuant to Section 12(b) of the Securities Exchange Act of 1934,
  as amended (the &ldquo;Exchange Act&rdquo;), as updated by the description of the Common Stock contained in Exhibit 4.7 to the Registrant&rsquo;s
  Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 11, 2020, including any amendment
  or report filed for the purpose of updating such description.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents subsequently filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
  Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold,
  shall be deemed to be incorporated herein by reference from the date of filing of such documents; provided, however, that any reports
  or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included
  with such items, shall not be deemed incorporated by reference in this Registration Statement. Any statement contained herein or in a
  document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for all purposes to the
  extent that a statement contained in this Registration Statement or in any other subsequently filed document which is incorporated by
  reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed, except as so modified
  or amended, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman; margin: 0pt 0; text-align: justify">Item 8. Exhibits.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 21%; text-align: left; font-weight: bold"><U>Exhibit Number</U></TD>
      <TD STYLE="width: 79%; text-align: justify; font-weight: bold"><U>Description of Exhibit</U></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-left: 9pt; text-align: justify; font-weight: bold">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-weight: normal">4.1</FONT></TD>
      <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1398733/000121465923010930/ex4_1.htm">Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (filed as Exhibit 4.1 to the Registration Statement on Form S-8 of the Registrant (File No. 333-273857), as filed on August 9, 2023 and incorporated by reference herein).</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-left: 9pt; text-align: justify; font-weight: bold">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-weight: normal">5.1</FONT></TD>
      <TD STYLE="text-align: justify"><A HREF="ex5_1.htm">Legal Opinion of Lori J. Braender, Chief Legal Officer and Corporate Secretary, filed herewith.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-left: 9pt; text-align: justify; font-weight: bold">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-weight: normal">23.1</FONT></TD>
      <TD STYLE="text-align: justify"><A HREF="ex23_1.htm">Consent of KPMG LLP, filed herewith.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-left: 9pt; text-align: justify; font-weight: bold">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-weight: normal">24.1</FONT></TD>
      <TD STYLE="text-align: justify"><A HREF="ex24_1.htm">Powers of Attorney, filed herewith (included on the signature page of this Registration Statement under the caption &ldquo;Power of Attorney&rdquo;).</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-left: 9pt; text-align: justify; font-weight: bold">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-weight: normal">107
  </FONT></TD>
      <TD STYLE="text-align: justify"><A HREF="ex107.htm">Filing Fee Table, filed herewith.</A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the County of Somerset, State of New Jersey, on this 24<SUP>th</SUP> day of January, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AQUESTIVE THERAPEUTICS, INC.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 45%">&nbsp;</TD>
      <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel R. Barber</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Daniel R. Barber</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "g122252s8.htm", "secsgml_size_bytes": 24467}]
metadata_filer: {"company-data": {"conformed-name": "Aquestive Therapeutics, Inc.", "cik": "0001398733", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "208623253", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-284490", "film-number": "25554769"}, "business-address": {"street1": "30 TECHNOLOGY DRIVE", "city": "WARREN", "state": "NJ", "zip": "07059", "phone": "908-941-1900"}, "mail-address": {"street1": "30 TECHNOLOGY DRIVE", "city": "WARREN", "state": "NJ", "zip": "07059"}, "former-company": {"former-conformed-name": "MonoSol Rx, Inc.", "date-changed": "20070507"}}
text: As filed with the Securities and Exchange Commission on January
  24, 2025
  Registration No. 333-_______
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, DC 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  Aquestive Therapeutics, Inc.
  (Exact name of registrant as specified in its charter)
  Delaware
  30 Technology Drive
  Warren, NJ 07059
  82-3827296
  (State or Other Jurisdiction of
  Incorporation or Organization)
  (Address of Principal Executive
  Offices)
  (Zip Code)
  (
  I.R.S. Employer Identification No.)
  Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as
  amended
  (Full title of the plan)
  A. Ernest Toth, Jr.
  Chief Financial Officer
  Aquestive Therapeutics, Inc.
  30 Technology Drive
  Warren, NJ 07059
  (Name and address of agent for service)
  (908) 941-1900
  (Telephone number, including area code, of agent for service)
  Copies of all communications to
  :
  Lori J. Braender
  Chief Legal Officer and Corporate Secretary
  Aquestive Therapeutics, Inc.
  30 Technology Drive
  Warren, NJ 07059
  908-941-1900
  Indicate by check mark whether the
  registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  o
  Accelerated filer
  o
  Non-accelerated filer
  ý
  Smaller reporting company
  ý
  Emerging growth company
  o
  If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  o
  EXPLANATORY NOTE
  This Registration Statement is being filed
  by Aquestive Therapeutics, Inc. (the "Registrant") for the purpose of registering an additional 3,656,549 shares of common
  stock, par value $0.001 per share (the "Common Stock"), of the Registrant available for issuance under the Aquestive Therapeutics,
  Inc. 2018 Equity Incentive Plan, as amended (the "2018 Plan"), pursuant to provisions of the 2018 Plan providing for an automatic
  increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan. The Registrant previously filed
  with the Securities and Exchange Commission (the "Commission") registration statements on Form S-8 on July 27, 2018 (File
  No. 333-226399), January 8, 2021 (File No. 333-251984), January 7, 2022 (File No. 333-262051), January 18, 2023 (File No. 333-269292),
  August 9, 2023 (File No. 333-273857), and February 12, 2024 (File No. 333-277015) (collectively, the "Prior Registration Statements")
  registering shares of Common Stock issuable under the 2018 Plan. This Registration Statement relates to securities of the same class as
  those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding
  Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements
  are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by
  this Registration Statement below.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The following documents, as originally filed
  with the Commission by the Registrant, are incorporated herein by reference; provided, however, that any reports or portions thereof that
  are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall
  not be deemed incorporated by reference in this Registration Statement:
  (a)
  The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with
  the Commission on March 5, 2024;
  (b)
  The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with
  the Commission on May 7, 2024;
  (c)
  The Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the
  Commission on August 6, 2024;
  (d)
  The Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with
  the Commission on November 4, 2024;
  (e)
  The
  Registrant's Current Reports on Form 8-K, filed with the Commission on March 15, 2024, March 21, 2024, April 1, 2024, April 22,
  2024, April 29, 2024, June 6, 2024, June 21, 2024, July 25, 2024, August 14, 2024, September 27, 2024, October 16, 2024, October 24,
  2024, October 25, 2024, November 7, 2024, December 2, 2024, and December 19, 2024; and
  (f)
  The description of the Common Stock contained in the Registrant's Registration Statement on Form
  8-A (File No. 001-38599) filed with the Commission on July 20, 2018, pursuant to Section 12(b) of the Securities Exchange Act of 1934,
  as amended (the "Exchange Act"), as updated by the description of the Common Stock contained in Exhibit 4.7 to the Registrant's
  Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 11, 2020, including any amendment
  or report filed for the purpose of updating such description.
  All documents subsequently filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
  Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold,
  shall be deemed to be incorporated herein by reference from the date of filing of such documents; provided, however, that any reports
  or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included
  with such items, shall not be deemed incorporated by reference in this Registration Statement. Any statement contained herein or in a
  document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for all purposes to the
  extent that a statement contained in this Registration Statement or in any other subsequently filed document which is incorporated by
  reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed, except as so modified
  or amended, to constitute a part of this Registration Statement.
  Item 8. Exhibits.
  Exhibit Number
  Description of Exhibit
  4.1
  Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (filed as Exhibit 4.1 to the Registration Statement on Form S-8 of the Registrant (File No. 333-273857), as filed on August 9, 2023 and incorporated by reference herein).
  5.1
  Legal Opinion of Lori J. Braender, Chief Legal Officer and Corporate Secretary, filed herewith.
  23.1
  Consent of KPMG LLP, filed herewith.
  24.1
  Powers of Attorney, filed herewith (included on the signature page of this Registration Statement under the caption "Power of Attorney").
  107
  Filing Fee Table, filed herewith.
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the County of Somerset, State of New Jersey, on this 24
  th
  day of January, 2025.
  AQUESTIVE THERAPEUTICS, INC.
  By:
  /s/ Daniel R. Barber
  Name:
  Daniel R. Barber
  Title:
  President and Chief Executive Officer